PATRICK KANE: Open Payments
NPI 1730576117 · NEPTUNE CITY, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$583 in 31 payments from 12 companies in 2025. Trend: 2023 $438 · 2024 $552 · 2025 $583
Food & beverage: $583
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 7 | $141 |
| Neurocrine BioSciences, Inc. | 5 | $97 |
| ABBVIE INC. | 4 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $69 |
| Alkermes, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $37 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Lilly USA, LLC | 1 | $24 |
| Indivior Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: INGREZZA, SPRAVATO, VRAYLAR, INVEGA SUSTENNA, AUSTEDO XR, ARISTADA, Leqembi, COBENFY.
Industry payments across NJ — which companies pay providers there.
